Eris Lifesciences quarterly results and financials

Eris Lifesciences (ERIS)₹1,262+0.71%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Sep 2026 quarter (consolidated), Eris Lifesciences reported sales of ₹889 Cr, up 12.6% from Sep 2025, and net profit of ₹188 Cr, up 39.5% year on year. For the year to Mar 2026, sales were ₹3,118 Cr and net profit ₹651 Cr.

Sales (Sep 2026): ₹889 Cr
Net profit (Sep 2026): ₹188 Cr
Sales (FY Mar 2026): ₹3,118 Cr
Net profit (FY Mar 2026): ₹651 Cr
EPS (Sep 2026): ₹13.26
Borrowings (Mar 2026): ₹2,363 Cr

Company filings, consolidated accounts; latest reported quarter Sep 2026

Eris Lifesciences quarterly results

₹ crore unless stated; each column is a quarter.

Eris Lifesciences Quarterly results
	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Sales	485	549	718	738	725	703	770	789	804	754	871	889
Expenses	311	402	470	476	477	453	495	503	525	484	577	583
Operating Profit	176	148	251	266	251	253	278	289	283	273	297	309
OPM %	36.0%	27.0%	35.0%	36.0%	34.0%	36.0%	36.0%	36.0%	35.0%	36.0%	34.0%	35.0%
Other Income	4.01	15.05	2.01	5.02	4.01	8.03	4.02	3.01	−17.05	2.01	2.01	−33.13
Interest	17.94	32.90	59.83	58.81	56.85	53.84	48.85	49.88	48.82	45.86	46.86	45.84
Depreciation	45.89	53.86	75.84	79.74	80.72	76.76	70.80	68.79	69.85	69.77	71.76	72.80
Profit before tax	116	76.89	116	129	116	129	161	173	145	159	179	156
Tax %	11.9%	−4.0%	21.9%	25.0%	24.9%	21.0%	22.0%	22.0%	24.9%	−75.1%	19.9%	−20.0%
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	−12.98	0.00	0.00	−27.93
Net Profit	101	80.32	90.31	96.31	87.31	102	125	135	109	280	144	188
EPS (Rs)	7.54	5.21	6.11	6.74	6.14	6.88	8.65	8.83	7.31	20.35	10.29	13.26

Eris Lifesciences profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Eris Lifesciences Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	595	747	854	978	1,070	1,209	1,342	1,680	2,003	2,884	3,118	3,318
Expenses	425	479	532	636	701	780	857	1,145	1,331	1,874	2,008	2,169
Operating Profit	172	270	323	346	373	432	491	540	678	1,020	1,123	1,161
OPM %	29.0%	36.0%	38.0%	35.0%	35.0%	36.0%	36.0%	32.0%	34.0%	35.0%	36.0%	35.0%
Other Income	3.01	25.06	26.09	31.09	12.05	9.02	22.07	9.03	22.07	18.06	−9.03	−46.16
Interest	0.00	0.99	10.96	22.91	1.99	1.99	3.98	25.93	84.74	230	192	187
Depreciation	19.94	22.93	25.92	35.88	49.89	42.91	64.79	117	183	314	279	284
Profit before tax	154	270	312	317	331	394	441	405	430	488	638	639
Tax %	12.9%	9.0%	6.0%	8.0%	11.0%	10.0%	8.0%	8.0%	8.0%	23.0%	−1.0%	—
Exceptional items	1.99	2.99	2.99	0.99	3.99	1.99	−1.99	3.99	2.99	2.99	−12.96	−40.91
Net Profit	135	248	296	292	298	356	408	375	399	376	651	721
EPS (Rs)	9.53	17.94	21.40	21.16	21.85	26.18	29.90	28.11	28.81	25.83	44.76	51.21
Dividend payout %	63.0%	0.0%	0.0%	0.0%	13.0%	21.0%	20.0%	26.0%	0.0%	28.0%	16.0%	—

Eris Lifesciences balance sheet

₹ crore, at each year end.

Eris Lifesciences Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	0.15	0.15	13.99	14.02	14.02	14.02	14.02	14.00	14.03	14.04	14.04	14.02
Reserves	266	299	553	849	1,138	1,285	1,564	1,896	2,186	2,578	2,848	3,893
Borrowings	1.01	0.00	1.00	378	176	0.00	7.01	84.07	880	2,789	2,486	2,363
Other Liabilities	90.56	97.53	123	169	174	204	201	232	335	1,359	1,408	857
Total Liabilities	357	397	691	1,409	1,503	1,504	1,785	2,226	3,415	6,741	6,755	7,127
Fixed Assets	72.17	71.10	232	773	763	877	855	920	2,574	4,329	5,317	5,194
CWIP	0.00	0.00	0.00	0.00	2.99	3.99	1.99	26.91	21.91	19.95	66.78	170
Investments	167	190	302	365	356	77.91	293	519	36.96	15.97	66.87	61.85
Other Assets	119	136	157	271	383	543	636	760	782	2,376	1,304	1,701
Inventories	57.80	47.89	55.81	64.84	82.72	68.77	93.75	118	131	189	334	436
Trade receivables	24.07	25.07	49.07	67.13	84.17	157	140	161	294	423	460	682
Cash & equivalents	5.99	10.01	2.01	10.99	7.99	66.97	37.99	51.99	58.01	1,401	223	67.01
Total Assets	357	397	691	1,409	1,503	1,504	1,785	2,226	3,415	6,741	6,755	7,127

Eris Lifesciences cash flow

₹ crore, for each year.

Eris Lifesciences Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	89.82	131	200	234	222	270	374	377	291	485	1,061	537
Cash from investing activity	−92.25	−44.17	−185	−592	−5.02	123	−324	−321	−978	−1,835	−78.24	−370
Cash from financing activity	0.00	−83.96	−24.01	363	−221	−335	−81.89	−44.94	688	1,379	−881	−314
Net cash flow	−2.01	4.01	−8.02	8.03	−3.01	60.26	−30.09	14.04	5.02	38.12	105	−146
Capex	13.04	24.08	50.22	25.08	38.11	152	26.09	121	844	129	155	298
Free cash flow	76.94	108	150	210	186	125	349	258	−549	356	909	241
CFO / OP %	95.9%	96.9%	93.9%	93.9%	84.9%	87.0%	102.9%	93.9%	67.9%	86.9%	113.9%	59.0%

Eris Lifesciences ratios

Working-capital days and returns, by year.

Eris Lifesciences Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	17	17	25	29	32	54	43	45	64	78	59	80
Inventory days	223	178	195	178	196	148	145	166	136	182	171	200
Days payable	143	93	135	248	201	214	158	167	130	211	171	152
Cash conversion cycle	97	102	84	−40	28	−12	30	44	70	48	59	129
Working capital days	16	10	24	−12	−16	60	65	76	51	−295	−48	−70
ROCE %	47.0%	53.1%	60.0%	34.0%	26.0%	25.0%	27.0%	25.0%	17.0%	11.0%	12.0%	14.0%

Eris Lifesciences: frequently asked questions

What are the latest quarterly results of Eris Lifesciences?

For the Sep 2026 quarter, Eris Lifesciences reported sales of ₹889 Cr, up 12.6% year on year and net profit of ₹188 Cr, up 39.5% year on year. The operating margin was 35.0%.

What is the annual revenue of Eris Lifesciences?

Eris Lifesciences' sales for the year to Mar 2026 were ₹3,118 Cr; over the last twelve months they were ₹3,318 Cr.

What is the net profit of Eris Lifesciences?

Net profit for the year to Mar 2026 was ₹651 Cr, and ₹721 Cr over the last twelve months. Earnings per share over the same trailing period were ₹51.21.

How much debt does Eris Lifesciences have?

Eris Lifesciences reported borrowings of ₹2,363 Cr at Mar 2026, against cash and equivalents of ₹67.01 Cr.

What is the free cash flow of Eris Lifesciences?

Cash from operations was ₹537 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹241 Cr.

Loading…